Key Operational and Financial Clarifications:
- The company states unequivocally that its core business and sales remain completely unaffected by the development referenced in the prior announcement.
- It quantifies its exposure to the US market, clarifying that it is channeled through its Tanuku facility. This exposure accounts for approximately 6% of the company's consolidated Year-to-Date (YTD) revenue. The company confirms this revenue stream is also unaffected.
- Regarding future regulatory filings, the company specifies that new Abbreviated New Drug Applications (ANDAs) will be managed from its second API manufacturing facility located in Patalganga. This facility is confirmed to be US FDA approved.
- The Patalganga facility received zero observations in its most recent US FDA inspection and continues to operate normally.
Financial Guidance Impact:
- Based on its current assessment, Wanbury confirms there is absolutely no impact on its current financial guidance for the fiscal year 2026-27 (FY26-27).
- The company also confirms there is no impact on its overall operations for FY26-27 due to this development.
The letter is signed by Jitendra J. Gandhi, Company Secretary of Wanbury Limited.